MRSA Bacteremia Clinical Trial
Official title:
A Multicenter, Double-blinded, Randomized, Parallel Design, Phase IIa Clinical Trial to Evaluate the Efficacy, Safety and PK of LCB01-0371 With Vancomycin Versus Vancomycin Monotherapy in Patients With MRSA Bacteremia
The objectives of this study is to exploratory whether vancomycin + delpazolid is more effective to the standard of treatment (vancomycin)/ for hospitalised adults with MRSA bacteraemia.
The mortality from S aureus bacteremia is higher for MRSA than for methicillin-susceptible S aureus (MSSA), typically at 20% to 25%. The current standard therapy for MRSA bacteremia is vancomycin. Vancomycin has many shortcomings, including poor tissue penetration and slow killing time. Vancomycin has reduced efficacy against MRSA and tended to increase the MIC level (called MIC creep). Addition of Delpazolid to Vancomycin could improve the known drawbacks of Vancomycin alone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03096405 -
Impact MRSA -PCR on Patient Management
|
N/A | |
| Recruiting |
NCT06069206 -
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
|
N/A | |
| No longer available |
NCT04597242 -
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
|